Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a strategy that has led to a 45% increase in its ...

BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) rose 10% on Monday after J.P. Morgan raised its rating on the stock to overweight from neutral, based on in part on the launch of the drug Crexont.

JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption. Next: Get access to a new market-moving chart every day ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab biosimilars referencing Prolia and XGEVA. mAbxience ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million for the quarter, compared to analyst estimates of ...